Clinical Study on Prognostic Factors in Thyroid Carcinoma.

Tachikawa, Takuya; Kumazawa, Hirobumi; Kyomoto, Ryouichi; Yukawa, Hisaya; Yamashita, Toshio; Nishikawa, Mitsushige

doi:10.3950/jibiinkoka.104.157

Cited by 10 publications

(5 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although carcinomas often metastasize to the regional lymph nodes, prognosis is generally good because of the slow progression of the tumor. However, advanced age, the presence of deep neck metastasis, distant metastasis, extracapsular invasion and tumor diameters are other prognostic factors that must be taken into account 1–7 . In addition, fixed lymph node metastasis 8 and gross nodal metastasis 9 are also indicators of a poor prognosis from the perspective of lymph node metastasis.…”

mentioning

confidence: 99%

Increased expression of integrin β‐4 in papillary thyroid carcinoma with gross lymph node metastasis

Hosaka

Hiraumi

Hirose

et al. 2002

Pathology International

View full text Add to dashboard Cite

Although the prognosis is generally good for patients with papillary thyroid carcinoma, gross nodal metastasis of carcinoma has a poor prognosis. It is necessary to clarify how carcinoma progresses to gross nodal metastasis in order to establish a cure. The adhesion molecule integrin beta-4 is considered to be related to cell migration and metastasis in many carcinomas. In the present study, we examined integrin beta-4 expression in 65 cases of human papillary thyroid carcinoma using immunohistochemical methods. Expression of integrin beta-4 was found in all papillary carcinomas, but in few normal thyrocytes. Interestingly, integrin beta-4 expression in the carcinomas with gross (> or =3 cm) lymph node metastasis was significantly higher than that in carcinomas with small (<3 cm) or no lymph node metastasis. These results suggest that integrin beta-4 expression in thyroid carcinoma may play a role in the development of gross lymph node metastasis of papillary carcinomas.

show abstract

mentioning

confidence: 99%

Increased expression of integrin β‐4 in papillary thyroid carcinoma with gross lymph node metastasis

Hosaka

Hiraumi

Hirose

et al. 2002

Pathology International

View full text Add to dashboard Cite

show abstract

“…The 23 studies concerned 10,541 patients (2,330 ENE+ and 8,211 ENE−) with a median follow‐up of 120 months (range: 1–351) (Supplementary Table S1). The median NOS score was six points, and nine studies were at potentially high risk of bias (Supplementary Tables S1–2).…”

Section: Resultsmentioning

confidence: 99%

“…Pooling data from eight studies , 70.3% of patients with ENE+ were dead versus 30.2% with ENE−, leading to a significantly higher all‐cause mortality risk for the former (RR = 3.25; 95%CI: 1.35–2.64, P = 0.008, I 2 = 83%) (Table ; Supplementary Fig. S1).…”

Section: Resultsmentioning

confidence: 99%

Prognostic impact of extra‐nodal extension in thyroid cancer: A meta‐analysis

Veronese

Luchini²,

Nottegar³

et al. 2015

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…M+ stage has a negative influence on prognosis (53% survival at 5 years, 38% at 10 years, 30% at 15 years) (30). The localization of metastases would have a prognostic value too, but always negative in comparison with any variables (31,32); similarly, extrathyroid invasion has a particulary unfavourable prognostic mean (33)(34)(35).…”

Section: Stagementioning

confidence: 99%

Surgical treatment of differentiated thyroid carcinoma: a retrospective study

Sperlongano

Parmeggiani²,

Pisaniello³

et al. 2006

Front Biosci

View full text Add to dashboard Cite

A retrospective study was carried out to assessed reliability of the prognostic factors (histology, age, sex, and stage), and standard procedures for the surgical treatment of differentiated thyroid cancers (DTC). From the 144 DTC cases reviewed with follow-up ranging from 1 to 25 years (m = 6.33 years), total mortality for cancer was found to be 55% (8 patients), with a predictive positive value for recurrence of 95.4% and 91.8% at 12 and 24 months, respectively. Median survival was 8.8 years (range 1 to 25 years). The multivariate analysis showed that factors such as age > 45 years, histology of intermediate malignancy, size up to 1.5 cm, and presence of metastases, significantly worsened the prognosis, regardless of the intervention that was carried out. We suggest total thyroidectomy for the treatment of benign pathologies and confirmed or suspected cases of cancer. We reserve loboisthmectomy for the treatment of benign pathologies confined to one lobe or those with FNAB suggesting a follicular neoplasm.

show abstract

Clinical Study on Prognostic Factors in Thyroid Carcinoma.

Abstract: al: Analysis of thyroid carcinoma based on material registered in japan during 1977-1986 with special reference to predomi nance of papillary type. Cancer 70: 808-814 , 1992.

Cited by 10 publications

References 4 publications

Increased expression of integrin β‐4 in papillary thyroid carcinoma with gross lymph node metastasis

Increased expression of integrin β‐4 in papillary thyroid carcinoma with gross lymph node metastasis

Prognostic impact of extra‐nodal extension in thyroid cancer: A meta‐analysis

Surgical treatment of differentiated thyroid carcinoma: a retrospective study

Contact Info

Product

Resources

About